Histone deacetylase inhibitory and antioxidant activities of some ethanolic plant extracts: A novel therapeutic approach for cancer
Abstract
Keywords
Antioxidant activity , cancer , enzyme inhibition , histone deacetylase , plant extract.
Kaynakça
- Yang S, Huang Y, Zhao Q. Epigenetic alterations and inflammation as emerging use for the advancement of treatment in non-small cell lung cancer. Front Immunol. 2022;13:878740.
- Huynh NCN, Everts V, Ampornaramveth RS. Histone deacetylases and their roles in mineralized tissue regeneration. Bone Rep. 2017;7:33–40.
- Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D et al. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018;9:53.
- Chen D, Shen A, Fang G, Liu H, Zhang M, Tang S et al. Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer. Acta Pharm Sin B. 2016;6:93–9.
- Cerna T, Hrabeta J, Eckschlager T, Frei E, Schmeiser H, Arlt V et al. The histone deacetylase inhibitor valproic acid exerts a synergistic cytotoxicity with the DNA-damaging drug ellipticine in neuroblastoma cells. Int J Mol Sci. 2018;19:164.
- Wang Y, Abrol R, Mak JYW, Das Gupta K, Ramnath D, Karunakaran D et al. Histone deacetylase 7: A signalling hub controlling development, inflammation, metabolism and disease. FEBS J. 2023;290:2805-32.
- Chittur SV, Sangster-Guity N, McCormick PJ. Histone deacetylase inhibitors: A new mode for inhibition of cholesterol metabolism. BMC Genomics. 2008;9:507.
- Mottamal M, Zheng S, Huang T, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898–941.
- Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009;277:8–21.
- Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang BK et al. Depletion of HDAC1, 7 and 8 by histone deacetylase inhibition confers elimination of pancreatic cancer stem cells in combination with gemcitabine. Sci Rep. 2018;8:1621.
